Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views
Across the recent three months, 11 analysts have shared their insights on Intellia Therapeutics (NASDAQ:NTLA), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 4 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 4 | 1 | 0 |
Analysts have recently evaluated Intellia Therapeutics and provided 12-month price targets. The average target is $14.18, accompanied by a high estimate of $26.00 and a low estimate of $5.00. This current average represents a 31.6% decrease from the previous average price target of $20.73.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Intellia Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell S. Kapoor | HC Wainwright & Co. | Raises | Buy | $25.00 | $15.00 |
| Jonathan Miller | Evercore ISI Group | Lowers | In-Line | $8.00 | $17.00 |
| Joon Lee | Truist Securities | Lowers | Buy | $14.00 | $25.00 |
| Mitchell S. Kapoor | HC Wainwright & Co. | Lowers | Buy | $15.00 | $18.00 |
| Geulah Livshits | Chardan Capital | Lowers | Buy | $26.00 | $48.00 |
| Luca Issi | RBC Capital | Lowers | Sector Perform | $9.00 | $14.00 |
| Yanan Zhu | Wells Fargo | Lowers | Equal-Weight | $12.00 | $17.00 |
| Gena Wang | Barclays | Lowers | Overweight | $14.00 | $24.00 |
| David Nierengarten | Wedbush | Lowers | Neutral | $7.00 | $9.00 |
| Silvan Tuerkcan | Citizens | Lowers | Market Outperform | $21.00 | $29.00 |
| Brian Cheng | JP Morgan | Lowers | Underweight | $5.00 | $12.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intellia Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Intellia Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intellia Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Intellia Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Intellia Therapeutics
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics: Delving into Financials
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Intellia Therapeutics displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 51.27%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Intellia Therapeutics's net margin excels beyond industry benchmarks, reaching -735.19%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Intellia Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -13.85%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Intellia Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -11.11% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Intellia Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.13.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.